Ryan Stansfield

About Ryan Stansfield

Innovative and analytical scientist with experience in small molecule drug discovery and development. Proven track record of success with 7 programs progressing from discovery to clinical trials. Hands-on, in depth expertise in ADME, safety pharmacology, and toxicology. Excellent communicator, well organized, and efficient problem solver.

Experience

1. Director

   858 Therapeutics

   Nov 2022 — Present · San Diego, CA, US

   Effectively managed lead program’s 28-day GLP IND-enabling toxicology studies including genetic toxicology and safety pharmacology studies•Authored all ADME, toxicology, and select pharmacology non-clinical reports for a successful IND submission•Built out DMPK laboratory to enable the internal analysis of PK/TK samples, perform in vitro ADME assessment studies, and formulate test article for in vivo studies•Led DMPK/toxicology group including recruitment, mentorship, and development of a high-performing team of scientists and management of budget and timelines•Oversaw ADME, safety pharmacology, and toxicology preclinical activities to ensure timely and rigorous data enabling a positive IND submission•Collaborated with regulatory, CMC, and clinical team to develop strategy for on-going clinical development activities•Evaluated new targets and in-licensing opportunities as part of the executive diligence team to support expansion of portfolio

Education

• UC Santa Barbara

  B.S., Zoology

  1993 — 1997

Skills

• CRO
• Oncology
• Chemistry
• Clinical Development
• Protein Chemistry
• Cancer Research
• Mass Spectrometry
• Biochemistry
• Lc-Ms
• Drug Discovery
• Pharmaceutical Industry
• Glp
• Winnonlin
• R&D
• High Throughput Screening
• Pharmacokinetics
• Hplc
• CRO Management
• Drug Development
• Cancer
• Bioanalysis
• Chromatography
• Dmpk